Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl
Ograniczanie wyników
Czasopisma help
Lata help
Autorzy help
Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 24

Liczba wyników na stronie
first rewind previous Strona / 2 next fast forward last
Wyniki wyszukiwania
help Sortuj według:

help Ogranicz wyniki do:
first rewind previous Strona / 2 next fast forward last
EN
Among the major challenges related to Alzheimer’s disease (AD) is identifying biomarkers of the early AD stage in easily accessible blood samples, as an alternative to existing sophisticated (brain imaging) and invasive (cerebrospinal fluid, CSF) procedures for AD diagnosis. One of the promising approaches concentrates on circulating microRNAs (miRNAs). Using qRT-PCR we compared the miRNA profiles in the blood plasma of 15 mild cognitive impairment patients with early AD (MCI-AD), whose diagnoses were confirmed by CSF biomarkers, with 20 later AD patients and 15 non-demented, age-matched individuals (CTR). In the first screening, we assessed 179 plasma miRNAs. We confirmed 23 miRNAs reported earlier as AD biomarker candidates and found 26 novel differential miRNAs. For 15 statistically significant differential miRNAs, the TargetScan, MirTarBase and KEGG database analysis indicated putative targets among key proteins involved in AD pathology such as MAPT (tau), APP and enzymes of amyloidogenic proteolysis. These 15 miRNAs were verified in separate, subsequent AD, MCI-AD and CTR groups. Finally, 6 miRNAs were selected as the most promising biomarker candidates differentiating early AD from controls with the highest fold changes (from 1.32 to 14.72), consistent significance, specificities from 0.78 to 1 and sensitivities from 0.75 to 1), (patent pending, PCT/IB2016/052440). The identified miRNA panel in the blood could not only serve as an early non-invasive AD diagnostic, but could also indicate individualized therapy. FINANCIAL SUPPORT: This research was supported by the EU Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no 665735 (Bio4Med) and by the funding from the Polish Ministry of Science and Higher Education (agreement no 3548/ H2020/COFUND/2016/2). The work was carried out with the use of CePT infrastructure financed by the European Regional Development Fund within the Operational Programme “Innovative economy” for 2007–2013.
|
|
nr S
EN
Alzheimer’s disease (AD) is the most common age-related neurodegenerative dementia attributed to the amyloid beta (Aβ) deposition in the brain. Analysis of rare familiar (FAD) cases with mutations in presenilin, the proteins responsible for generation of Aβ from its precursor APP, firmed the ‘amyloid hypothesis’ of AD etiology. However, anti-amyloid therapies failed indicating that AD pathogenesis is more complex and involves additional mechanisms. Affected brain areas of AD patients and of animal FAD models showed increased levels of intracellular Ca2+, alterations in expression levels of Ca2+- signaling proteins and increased activation of Ca2+-dependent enzymes. Based on these data, the ‘Ca2+ hypothesis of AD’ has been proposed. Ca2+ contributes to the development of AD by Ca2+-triggered ER and mitochondrial dysfunction, and Ca2+- dependent changes in gene expression. The elevated cytosolic Ca2+ levels affect synaptic stability and function, and can activate death signaling. Moreover, the augmented cellular Ca2+ levels affect Aβ generation. In turn, Aβ generation potentiate Ca2+ dyshomeostasis in several ways. For example, Aβ causes impairment of NMDARs signaling while the released APP intracellular domain modulates Ca2+ homeostasis as the regulator of IP3-mediated Ca2+ efflux from the ER. Mutant presenilins contribute to Ca2+ dyshomeostasis as impaired ER Ca2+ leak channels and via interactions with Ca2+-signaling proteins such as calsenilin. Taken together, a growing body of evidence indicates that AD pathogenesis is based on the interplay between Ca2+ dyshomeostasis and neuropathological hallmarks of AD such as Aβ and mutated PS1. Thus, stabilizers of neuronal Ca2+ homeostasis and signaling may have therapeutic potential for AD treatment.
EN
Alzheimer's disease (AD) is a neurodegenerative disorder with a complex etiology and pathogenesis. Chromosome missegregation was proposed two decades ago to be responsible for neurodegeneration in AD patients. It was speculated that the aneuploidy is a result of aberrant cell cycle of neuronal progenitors during adult neurogenesis and/or of mature neurons. There is mounting evidence of increased rate of general aneuploidy and cell cycle reentry in the AD patients' brains, with area-specific pattern. In this review, we discuss the involvement of chromosome instability, genome damage and cell cycle impairment in AD pathology.
EN
INTRODUCTION: Prominent neuropathologic features of Alzheimer’s Disease (AD) are the appearance of senile plaques composed of amyloid peptides and neurofibrillary tangles derived from Tau protein. Induction of main risk factors before the appearance of typical neuropathological AD hallmarks can help to track the sequence of different and complicated early molecular mechanisms of the sporadic form of human AD (SAD). AIM(S): Our aim is to establish a mouse model that would mimic molecular mechanisms leading to SAD by induction of systemic neuroinflammation and insulin resistance in transgenic mice with mutated human gene encoding amyloid precursor protein (Tg APP). Additionally, we would like to check whether the same experimental conditions may induce AD hallmarks in wild type mice, that may be a proof of lifestyle factors influence on AD development. METHOD(S): In order to induce neuroinflammation and evaluate the influence of insulin dysregulation in the brain, Tg APP and C57BL mice were injected with LPS, and diabetes was induced by high-fat diet feeding, or streptozocin injection. Every two weeks blood glucose level and body weight were checked. To characterize the metabolic phenotype and immunostaining pattern of neuroinflammatory markers and amyloid β, mice blood and brain tissue were used. RESULTS: We show effects of systemic administration of infectious agent in neuroinflammation in the brain and body weight and blood biochemical pattern related to high-fat diet and their relation with amyloidopathy progression in the brain. CONCLUSIONS: The data verify if lifestyle conditions including ongoing systemic inflammation and metabolic changes related to unhealthy diet may accelerate amyloidopathy progression. Studied factors may cause changes not only in Tg APP mice but also lead to the development of AD hallmarks in brain of mice without mutations in APP gene. Results might provide the evidence that the proposed animal model may be an effective tool to study the molecular mechanisms of early stages of SAD progression. FINANCIAL SUPPORT: Polish National Science Centre Grant 2014/15/D/NZ4/04361.
EN
Alzheimer’s disease (AD) is the most common neurodegenerative disorder in which certain molecular changes are observed not only in neurons but also in peripheral cells. Growing evidence suggests that AD post-mitotic neurons exhibit increased apoptotic response to oxidative stress, mitochondria dysfunction and calcium dyshomeostasis. We hypothesized that some of these alterations could be observed in peripheral lymphocytes and studied for potential diagnostic purposes. We analyzed apoptotic response to the redox stress evoked by 2-deoxy-Dribose in immortalized lymphocytes from 18 patients with sporadic AD (SAD), from 2 familial AD (FAD) patients with novel mutations in presenilin 1: P117R and I213F, and from 20 agematched healthy individuals. Using two independent fl ow cytometry methods for quantifi cation of apoptosis, we found that SAD and FAD lymphocytes show enhanced apoptotic response to the redox stress. This apoptotic response was accompanied by decline in mitochondrial membrane potential measured with JC-1 as well as by increased activities of caspase 9 and caspase 3. However, no changes in the expression of two calcium-binding proteins: calmyrin 1 and calreticulin were observed. This study emphasizes that increased susceptibility to redox stress and associated upregulation of mitochondrial apoptotic pathway is characteristic not only for AD neurons, but also for AD lymphocytes. Thus, human lymphocytes could be used in further studies on AD pathogenesis.
EN
INTRODUCTION: The amyloid hypothesis postulates that the main cause of Alzheimer’s disease (AD) is amyloidogenic cleavage of amyloid precursor protein (APP) and deposition of amyloid‑beta. Recently, another hypothesis was formulated that neuroinflammation may precede amyloid generation in AD development. It was also demonstrated that systemic inflammation may impair brain homeostasis and function. AIM(S): Based on these data we hypothesized that systemic inflammation impairs brain homeostasis and leads to neuroinflammation that later causes AD development. METHOD(S): To verify this hypothesis, we compared effects of systemic inflammation induced by intraperitoneal injection of lipopolysaccharide (LPS) in transgenic mice expressing human APP with Swedish AD-causing mutation (APPswe) to untreated APPswe mice. To assess AD neuropathological hallmarks, brain tissue from 4, 8, and 12‑month old animals were analyzed by immunohistochemical staining and immunoblotting. RESULTS: We found that LPS shortly after peripheral administration to APPswe mice induced astrogliosis and dysregulation of pro- and anti-inflammatory cytokines in brains already in young 4‑month old animals and these effects were also detected in 8-month old mice. In control mice not treated with APPswe, the development of signs of neuroinflammation was slower. We also compared the signs of neuroinflammation in the hippocampus and entorhinal cortex to levels of APP full-length protein and its pathologically truncated CTFs forms. CONCLUSIONS: Obtained results indicate that systemic inflammation accelerates and intensifies neuroinflammation as reflected by astrogliosis and pro-inflammatory reaction during AD development. It suggests that systemic inflammation can be considered as a common civilization risk factor of AD progression. These data became the reference for the next hypothesis and studies of our group (abstracts by A. Mietelska‑Porowska and by A. Więckowska). FINANCIAL SUPPORT: Financed by National Science Center grants no. 2014/15/D/NZ4/04361, 2018/29/N/ NZ7/01724.
EN
INTRODUCTION: The western diet (WD), enriched in saturated fatty acids, cholesterol, and simple carbohydrates., is known to cause metabolic syndrome related to insulin metabolism impairment. On the other hand, metabolic syndrome is described as a potential risk factor for Alzheimer’s disease (AD). Main early AD features in brain are altered proteolysis of amyloid precursor protein (APP) and hyperphosphorylation of tau protein. AIM(S): Our aim was to verify our hypothesis that the WD causes insulin metabolism disturbances and may accelerate development of early AD hallmarks. METHOD(S): To verify this hypothesis, we compared effects of WD feeding (from 3rd month of age) in transgenic mice expressing human APP with Swedish AD-causing mutation (APPswe) compared to APPswe mice in which systemic inflammation was induced by injection of lipopolysaccharide (LPS; the model described in the abstract by J. Dlugosz), and to untreated APPswe mice. To assess AD neuropathological hallmarks, all groups were analysed at the ages of 4, 8, and 12‑months by immunohistochemical and immunoblotting analysis. RESULTS: Our results demonstrate levels of insulin resistance marker and insulin/Aβ degrading enzyme in relation to characteristic neuropathological AD hallmarks, such as occurrence, intensity of staining, and neuronal compartmentalisation of phosphorylated isoform of Tau protein, and the level of APP full-length protein and its pathologically truncated CTFs forms, in the hippocampus and cortex of mice brains. CONCLUSIONS: Obtained results indicate that WD is linked to insulin metabolism impairment and leads to accelerated over-phosphorylation of tau protein and proteolysis of APP. This suggests that the WD, via impairment in insulin metabolism, may accelerate the development of AD. FINANCIAL SUPPORT: Financed by National Science Center grant no. 2014/15/D/NZ4/04361.
EN
INTRODUCTION: A diet enriched in fat, cholesterol, and sugar – called the Western diet (WD) – was shown to induce systemic inflammation, obesity, and metabolic syndrome and results directly and indirectly in an impact on brain structure and function. The WD has not been examined yet in the context of Alzheimer’s disease (AD), characterised by altered cleavage of amyloid precursor protein (APP) and deposits of toxic amyloid. AIM(S): We aimed to verify the hypothesis that WD by inducing metabolic syndrome and systemic inflammation may accelerate brain glia activation events and the onset of AD. METHOD(S): To verify this hypothesis, transgenic mice expressing human APP with Swedish AD-causing mutation (APPswe) were fed with WD from 3rd month of age. These mice were compared to APPswe mice in which systemic inflammation was induced by injection of lipopolysaccharide (LPS) and to untreated APPswe mice. All animal groups were subsequently analysed at the age of 4, 8, and 12‑months by immunohistochemical and immunoblotting analysis. RESULTS: Already one month of WD feeding induces metabolic disturbances including hypercholesterolemia and hyperglycaemia and accelerates the brain pathological events in young APPswe mice. After one month of WD feeding, we observed enhanced astrogliosis, altered profile of microglia activation state, and enhanced cleavage of APP in mice brains. Moreover, we observed obesity, enhanced liver weight, and non-alcoholic fatty liver disease (NAFLD) after 3 months of the WD, which suggest that the WD causes alterations in the brain even earlier than in peripheral organs. CONCLUSIONS: These results suggest that the WD leads to brain neuroinflammation and accelerates the development of AD. Therefore, the WD can be considered as a newly identified common civilian AD risk factor. FINANCIAL SUPPORT: Supported by National Science Center grants: 2014/15/D/NZ4/04361, 2018/29/N/ NZ7/01724.
EN
Calmyrin 2 (CaMy2, Cib2) represents a novel calmyrin subfamily of Ca2+ binding proteins that coordinate Ca2+ in the EF-hand motives. CaMy2 mRNA was recently detected in brain, but nothing is known about CaMy2 protein localization and properties in the brain. We have cloned CaMy2 from rat brain, demonstrated CaMy2 Ca2+- sensor properties and determined its neuronal pattern of rat brain expression. CaMy2 protein is expressed mainly in hippocampal neurons and localizes together with Golgi apparatus and dendrite markers. Our studies in primary cultures of hippocampal neurons demonstrate that expression of CaMy2 protein is induced upon neuronal activation with pharmacological agents that stimulate Ca2+ infl ux through such types of Ca2+ channels as glutamate excitatory receptors and voltage-operated Ca2+ channels. In addition, increase in CaMy2 protein level was induced by soluble amyloid β and BDNF. However, most prominent increase in CaMy2 protein (7-fold), and mRNA (2-fold) occurs upon stimulation of NMDA receptor (NMDAR). The induction is blocked by translation inhibitors, specifi c antagonists of NMDAR, the Ca2+-chelator BAPTA, and inhibitors of ERK1/2 and PKC, kinases transmitting NMDAR-linked Ca2+ signal. Our results show that CaMy2 level is controlled by NMDAR and Ca2+ and suggest CaMy2 role in Ca2+ signaling underlying NMDAR activation. This work was supported by the Polish Ministerial Research grant N301 109 32/3854.
EN
The EF-hand Ca2+-binding protein calmyrin is expressed in many tissues and can interact with multiple effector proteins, probably as a sensor transferring Ca2+ signals. As oligomerization may represent one of Ca2+-signal transduction mechanisms, we characterised recombinant calmyrin forms using non-reducing SDS/PAGE, analytical ultracentrifugation and gel filtration. We also aimed at identification of biologically active calmyrin forms. Non-reducing SDS/PAGE showed that in vitro apo- and Ca2+-bound calmyrin oligomerizes forming stable intermolecular disulfide bridges. Ultracentrifugation indicated that at a 220 μM initial protein concentration apo-calmyrin existed in an equilibrium of a 21.9 kDa monomer and a 43.8 kDa dimer (trimeric or tetrameric species were not detected). The dimerization constant was calculated as Ka = 1.78 × 103 M–1 at 6oC. Gel filtration of apo- and Ca2+-bound calmyrin at a 100 μM protein concentration confirmed an equilibrium of a monomer and a covalent dimer state. Importantly, both monomer and dimer underwent significant conformational changes in response to binding of Ca2+. However, when calmyrin forms were analyzed under non-reducing conditions in cell extracts by Western blotting, only monomeric calmyrin was detected in human platelets and lymphocytes, and in rat brain. Moreover, in contrast to recombinant calmyrin, crosslinking did not preserve any dimeric species of calmyrin regardless of Ca2+ concentrations. In summary, our data indicate that although calmyrin forms stable covalent dimers in vitro, it most probably functions as a monomer in vivo.
first rewind previous Strona / 2 next fast forward last
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.